Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)

- First approved allogeneic cell therapy product globally for the treatment of CLI

- Developed by Stempeutics over a period of twelve years, breakthrough treatment designed to address root cause of the disease at an affordable cost

- Cipla to market and distribute the drug in India to provide patient access

Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)

MUMBAI, India, Aug. 21, 2020 /PRNewswire/...

Read more: Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to t...

More Articles …

  1. Industry Aficionado Paul Peros Launches World's First Tech-led Full Haircare Precision System-PR Newswire APAC
  2. Party at Home with DJ Tigerlily, Jesabel and Brooklyn on Bigo Live-PR Newswire APAC
  3. Ultima United Limited enters into a binding letter of intent -- Master Lease of Cannington Project-PR Newswire APAC
  4. Higher Logic Australia Has Grown its Customer Base by Over 250% Since the Start of 2020-PR Newswire APAC
  5. US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma-PR Newswire APAC
  6. Streamline End-to-end Records and Ensure Compliance with Newgen's Advanced Records Management System-PR Newswire APAC
  7. Nintex Turns 'Victorian Worker Permit' into a Fully Digital, Mobile Experience-PR Newswire APAC
  8. Nespresso invests in the Democratic Republic of Congo's coffee revival to bring back to life one of the world's most exclusive and finest coffees and improve thousands of lives in Kivu
  9. Sinorbis launches virtual student recruitment fair for China-PR Newswire APAC
  10. Australia Expects to Secure More Hollywood Film Productions to Gold Coast's Village Roadshow Studios on COVID-19 Road to Recovery-PR Newswire APAC